Get the Stockscreener App
0.96
3.77%
-0.0376
After Hours:
.93
-0.03
-3.12%
Redhill Biopharma Ltd Adr stock is traded at $0.96, with a volume of 21,163.
It is down -3.77% in the last 24 hours and down -24.41% over the past month.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
See More
Previous Close:
$0.9976
Open:
$0.991
24h Volume:
21,163
Relative Volume:
0.04
Market Cap:
$4.91M
Revenue:
$35.75M
Net Income/Loss:
$11.57M
P/E Ratio:
-0.2522
EPS:
-3.8069
Net Cash Flow:
$-26.25M
1W Performance:
-9.43%
1M Performance:
-24.41%
6M Performance:
-24.41%
1Y Performance:
-82.61%
1-Day Range:
$0.96
$0.9944
1-Week Range:
$0.96
$1.1114
52-Week Range:
$0.905
$5.75
Redhill Biopharma Ltd Adr Stock (RDHL) Company Profile
Compare RDHL vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RDHL
Redhill Biopharma Ltd Adr
|
0.96 | 5.10M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.28 | 57.18B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
128.67 | 56.47B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.16 | 49.16B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.31 | 40.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
475.85 | 20.37B | 3.13B | 1.27B | 1.12B | 26.39 |
Redhill Biopharma Ltd Adr Stock (RDHL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-31-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-11-20 | Initiated | BTIG Research | Buy |
| Jul-12-19 | Upgrade | WBB Securities | Buy → Strong Buy |
| Mar-12-19 | Upgrade | WBB Securities | Speculative Buy → Buy |
| Jan-26-18 | Initiated | Nomura | Buy |
| Oct-06-17 | Initiated | Seaport Global Securities | Buy |
| Oct-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-17 | Reiterated | FBR & Co. | Outperform |
| Jul-27-16 | Reiterated | FBR Capital | Outperform |
| Sep-29-15 | Initiated | Nomura | Buy |
| Jul-29-15 | Reiterated | ROTH Capital | Buy |
| Jun-17-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-15 | Reiterated | ROTH Capital | Buy |
View All
Redhill Biopharma Ltd Adr Stock (RDHL) Latest News
RedHill Biopharma Calls March 5, 2026 Extraordinary Meeting to Approve RSU Grants and Share Capital Increase - TipRanks
RDHL Stock Price, Forecast & Analysis | REDHILL BIOPHARMA LTD-SP ADR (NASDAQ:RDHL) - Chartmill
Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket - Benzinga
Redhill Biopharma stock soars on GLP-1 side effect treatment progress By Investing.com - Investing.com South Africa
Redhill Biopharma stock soars on GLP-1 side effect treatment progress - Investing.com India
RedHill advances once-daily ondansetron tablet for GLP-1 side effects - Investing.com
RedHill advances once-daily ondansetron tablet for GLP-1 side effects By Investing.com - Investing.com India
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects - Finviz
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells - Sahm
CapEx per share of RedHill Biopharma Ltd. Sponsored ADR – FWB:2RH - TradingView — Track All Markets
Redhill Biopharma Ltd. (RDHL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
RedHill Biopharma regains compliance with Nasdaq listing requirements By Investing.com - Investing.com South Africa
RedHill Biopharma regains compliance with Nasdaq listing requirements - Investing.com
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement - Finviz
Redhill Biopharma (NASDAQ:RDHL) versus ARS Pharmaceuticals (NASDAQ:SPRY) Head-To-Head Review - Defense World
Are Smart Investors Making the Right Decision? SmartKem Inc (SMTK) - setenews.com
RedHill Biopharma increases maximum amount for at-the-market ADS offering - Investing.com
VNET Group Inc ADR (VNET) expanding its growth trajectory ahead - Setenews
Nothing is Better Than Redhill Biopharma Ltd. ADR (RDHL) stock at the moment - Setenews
RedHill Biopharma wins $10.5 million court judgment against Kukbo By Investing.com - Investing.com India
RedHill Biopharma wins $10.5 million court judgment against Kukbo - Investing.com
Redhill Biopharma stock jumps after court win against Kukbo By Investing.com - Investing.com South Africa
Redhill Biopharma stock jumps after court win against Kukbo - Investing.com India
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement - Barchart.com
RedHill Biopharma to appeal Nasdaq compliance notice - Investing.com India
RedHill Biopharma to appeal Nasdaq compliance notice By Investing.com - Investing.com South Africa
RDHL appeals Nasdaq notice; 180-day extension possible - Stock Titan
RedHill Biopharma Receives Nasdaq Staff Determination Notification - Benzinga
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal - PR Newswire
CID Holdco Inc (DAIC): What Does Valuation Ratios Tell Us? - fostersleader.com
Lixte Biotechnology Holdings Inc (LIXT): What Technical Indicators Show - fostersleader.com
Cumberland invests $4 million for 30% stake in RedHill’s Talicia business By Investing.com - Investing.com
RedHill Biopharma Receives Nasdaq Staff Determination Notification - Barchart.com
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia® - Sahm
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia - Finviz
RedHill Biopharma stock surges after court upholds $10M judgment - Investing.com
RedHill Biopharma stock surges after court upholds $10M judgment By Investing.com - Investing.com South Africa
Is RDHL Poised for Rebound? Analyzing Financial Moves - StocksToTrade
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo - Sahm
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights - Placera.se
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million - PR Newswire
RedHill Biopharma receives Nasdaq extension to regain compliance by October - Investing.com
Redhill Biopharma stock soars after FDA provides positive pathway for Crohn’s drug - Investing.com
RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress - Finansavisen
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency - PR Newswire
Redhill Biopharma stock hits 52-week low at $2.47 amid steep annual decline - Investing.com
Redhill Biopharma stock hits 52-week low at $3 amid steep annual decline - Investing.com
Hyloris secures global rights to RedHill's RHB-102 - Investing.com
RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published - PR Newswire
Redhill Biopharma Ltd Share Price ADR Each Representing 1000 Ord Shares SPON - Hargreaves Lansdown
Talicia® Launched in the United Arab Emirates - PR Newswire
Redhill Biopharma Ltd Adr Stock (RDHL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):